
TILs Plus Pembro Show Efficacy in GI Cancers
Neoantigen-specific tumor-infiltrating lymphocytes (TILs) plus pembrolizumab demonstrate efficacy against treatment-refractory gastrointestinal (GI) cancers in early results from a phase 2 trial. This is the first clinical trial to show that TILs can …